Treatment Strategy: Early and Localized Disease

When esophageal adenocarcinoma (EAC) or esophagogastric junction (EGJ) cancer is caught in its early or localized stages, the primary goal of treatment is a cure. The strategy your team chooses depends on how deep the tumor has grown and how well your body can handle different types of therapy ^[1]. Recent clinical trials have fundamentally changed how doctors approach these stages, offering more effective options than ever before.

Early Stage (T1): Minimally Invasive Options

If your cancer is very shallow (called T1a), meaning it is only in the top layer of the esophageal lining, you may not need major surgery ^[2]. Instead, your doctor can use Endoscopic Eradication Therapy (EET). This is a family of procedures where a specialist uses an endoscope to remove the tumor without making any incisions ^[3]. The two most common techniques are:

• Endoscopic Mucosal Resection (EMR): The tumor is essentially suctioned and “shaved” or snared off the esophageal wall.
• Endoscopic Submucosal Dissection (ESD): A more advanced technique where the surgeon cuts beneath the tumor to remove it in one larger piece.
• Benefits: This approach has a much faster recovery time and fewer complications than surgery, with similar long-term success for very early cases ^[2][4].
• Note: If the tumor has grown deeper into the second layer (T1b) or shows aggressive features under the microscope, your team will likely recommend major surgery to ensure all the cancer is gone ^[3][5].

Locally Advanced (Resectable): A Major Shift in Care

For cancers that have grown deeper into the esophageal wall or spread to nearby lymph nodes, the standard of care is multimodal therapy—a combination of treatment before, during, and sometimes after surgery ^[6].

Until recently, the most common approach was the CROSS regimen (chemoradiotherapy followed by surgery). However, a landmark study called the ESOPEC trial has led to a major shift in the “preferred” treatment for many patients ^[7][8]:

• The Findings: The trial compared the CROSS regimen to FLOT (a “perioperative” chemotherapy regimen given both before and after surgery) ^[7].
• The Result: Patients who received FLOT lived significantly longer. The median overall survival for the FLOT group was 66 months, compared to 37 months for those who received the CROSS regimen ^[8].
• Why It Works: FLOT appears to be better at killing microscopic cancer cells that may have traveled elsewhere in the body (systemic control), reducing the risk of the cancer returning in other organs ^[9].

Note on Fitness and Side Effects: FLOT is considered an intensive chemotherapy regimen. It is highly effective, but it carries a higher risk of side effects like neutropenia (a severe drop in white blood cells increasing infection risk), neuropathy (nerve damage, often tingling or numbness in the hands and feet from the oxaliplatin drug), and extreme fatigue ^[10][11]. Your MDT will help you decide if you are physically “fit” enough for this approach.

The Surgical Reality: What to Expect in the Hospital

Regardless of the regimen you choose, surgery (esophagectomy or gastrectomy) remains a cornerstone of treatment ^[12]. It is important to know that this is a major physical undertaking.
The entire journey—from starting your first chemotherapy session to feeling fully recovered from surgery—typically spans 6 to 9 months. The surgery itself usually requires a 1 to 2-week hospital stay. This often begins with a few days in the Intensive Care Unit (ICU) to closely monitor your recovery. Immediate surgical risks that your team will monitor for include pneumonia or an “anastomotic leak” (a complication where the new connection in your digestive tract leaks).

“Cleanup” Therapy

After surgery, your team will look at the tissue to see how much cancer is left:

• Adjuvant Nivolumab: If you received the CROSS regimen (radiation + chemo) and the pathologist still finds viable cancer cells in the removed tissue—known as residual disease—the standard of care is now to receive an immunotherapy called nivolumab for up to a year ^[13][14]. This “cleanup” therapy significantly reduces the risk of the cancer coming back ^[15].